SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials
Related Experiment Video
Updated: Feb 7, 2026

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
Published on: October 10, 2020
Xiaoming Jia1, Paras B Mehta2, Yumei Ye3
1The Section of Cardiology, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. Xiaoming.jia@bcm.edu.
Purpose Of Review:
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to exert benefit on cardiac outcomes. In this review, we provide updates on available clinical data, studies on potential mechanisms for the CV effects, as well as discuss potential clinical implications of these new findings.
Recent Findings:
Since the publications of the EMPA-REG and CANVAS trials, large multi-national cohort studies have further shown the cardioprotective effects of SGLT2i. Moreover, new studies examining SGLT2i action on sodium-hydrogen exchanger proteins in both the heart and the kidney, on myocardial energetics and impact on inflammation and atherosclerosis continue to shed light on the multitude of pleotropic effects of these agents. Though more data is needed to substantiate the safety and efficacy, SGLT2i should be considered as a valuable therapy to help reduce CV risk in patients with diabetes. Ultimately, SGLT2i may have utility in preventing progression to diabetes or providing CV protection in patients who do not have diabetes.
Insights
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) offer significant cardiac benefits. Emerging research explores their mechanisms and potential to reduce cardiovascular risk in diabetic and non-diabetic individuals.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are established therapies for diabetes.
- Clinical trials like EMPA-REG and CANVAS demonstrated SGLT2i's cardiovascular benefits.
Purpose of the Study:
- To review current clinical data on SGLT2 inhibitors and cardiac outcomes.
- To explore the mechanistic pathways underlying the cardiovascular effects of SGLT2 inhibitors.
- To discuss the clinical implications of recent findings regarding SGLT2 inhibitors.
Main Methods:
- Review of large multi-national cohort studies.
- Analysis of recent research on SGLT2 inhibitor mechanisms.
- Synthesis of clinical trial data and observational studies.
Main Results:
- SGLT2 inhibitors demonstrate consistent cardioprotective effects.
- New studies investigate SGLT2i's impact on sodium-hydrogen exchange, myocardial energetics, inflammation, and atherosclerosis.
- Pleiotropic effects of SGLT2 inhibitors are increasingly understood.
Conclusions:
- SGLT2 inhibitors are valuable for reducing cardiovascular risk in patients with diabetes.
- Further research is needed to confirm safety and efficacy.
- SGLT2 inhibitors may offer potential benefits in diabetes prevention and cardiovascular protection for non-diabetic populations.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Predicting Reaction Outcomes
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Overview of the Cardiovascular System
Heart
The heart is the central pump of the cardiovascular system that circulates blood throughout the body. It comprises two atria receiving the blood and two ventricles pumping blood out of the heart. Their rhythmic contractions, called heartbeats, ensure that blood flow remains continuous.
Blood Vessels
Blood...
Criticisms of the Evolutionary Perspective
Evolutionary psychology provides one explanation for these findings, suggesting...

